<DOC>
	<DOCNO>NCT01213251</DOCNO>
	<brief_summary>The purpose study demonstrate feasibility pacing therapy prevent adverse remodel myocardium follow acute myocardial infarction ( MI ) patient high risk adverse myocardial remodeling .</brief_summary>
	<brief_title>Post-Myocardial Infarction Remodeling Prevention Therapy</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Myocardial Infarction ( MI ) within past 10 day Peak Creatine Phosphokinase ( CPK ) great 3000 Units/Litre ( U/L ) time MI , troponin T ( TnT ) great 10 micrograms/Litre ( mcg/L ) At least 18 year old Willing comply protocol Documented MI great 10 day Chronic renal disease , define estimate glomerular filtration rate ( eGFR ) less 30 milliliters/minute/1.73 square meter Life expectancy le 18 month , determine physician Existing pacemaker , Implantable Cardioverter Defibrillator ( ICD ) , Cardiac Resynchronization Therapy ( CRT ) device QRS duration great 120 millisecond ( m ) Coronary Artery Bypass Graft ( CABG ) within 30 day prior MI , CABG procedure plan Third degree atrioventricular ( AV ) block symptomatic bradyarrhythmia Persistent atrial fibrillation ( AF ) self terminate within 7 day terminate electrically pharmacologically Permanent AF non self terminating , cardioversion fail attempt within past year New York Heart Association ( NYHA ) Class IV Nonischemic cardiomyopathy Pregnant planning become pregnant study Enrolled plan participate concurrent drug and/or device study course clinical trial . Coenrollment concurrent trial allow documented preapproval Medtronic , document concern coenrollment could confound result trial . Breast feeding Of vulnerable population determine local law requirement , physician</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>